173 related articles for article (PubMed ID: 7828168)
21. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
22. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
[TBL] [Abstract][Full Text] [Related]
23. Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response.
Galligioni E; Favaro D; Santarosa M; Quaia M; Spada A; Freschi A; Alberti D
Clin Cancer Res; 1995 May; 1(5):493-9. PubMed ID: 9816008
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
25. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
26. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
Sone S; Utsugi T; Tandon P; Ogawara M
Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
[TBL] [Abstract][Full Text] [Related]
27. Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis.
Shabtai M; Ye H; Kono K; Takayam T; Terashima K; Tsukuda K; Frischer Z; Waltzer WC; Malinowski K
Urol Oncol; 2003; 21(1):27-32. PubMed ID: 12684124
[TBL] [Abstract][Full Text] [Related]
28. Effects of Liposome-Entrapped Muramyl Tripeptide Phosphatidylethanolamine (L-MTP-PE) on the Tumor Growth and Survival of Mice Bearing Syngeneic Tumor in Combination with a Chemotherapeutic or Immunomodulatory Agent.
Tanaka M; Abe S
Drug Res (Stuttg); 2022 Sep; 72(7):372-377. PubMed ID: 35767993
[TBL] [Abstract][Full Text] [Related]
29. Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine.
Killion JJ; Bucana CD; Radinsky R; Dong Z; O'Reilly T; Bilbe G; Tarcsay L; Fidler IJ
Cancer Biother Radiopharm; 1996 Dec; 11(6):363-71. PubMed ID: 10851497
[TBL] [Abstract][Full Text] [Related]
30. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
31. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
[TBL] [Abstract][Full Text] [Related]
32. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells.
Galligioni E; Quaia M; Spada A; Favaro D; Santarosa M; Talamini R; Monfardini S
Int J Cancer; 1993 Sep; 55(3):380-5. PubMed ID: 8375921
[TBL] [Abstract][Full Text] [Related]
33. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
Kowalczyk D; Skorupski W; Kwias Z; Nowak J
Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
35. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells.
Smith BW; Kurzman ID; Schultz KT; Czuprynski CJ; MacEwen EG
Cancer Biother; 1993; 8(2):137-44. PubMed ID: 7804354
[TBL] [Abstract][Full Text] [Related]
36. Activation of rat Kupffer cells to tumoricidal cells by the immunomodulator muramyl tripeptide-phosphatidylethanolamine incorporated into the novel drug carrier lactosylated low density lipoprotein.
van de Water B; van Berkel TJ; Kuiper J
Mol Pharmacol; 1994 May; 45(5):971-7. PubMed ID: 8190111
[TBL] [Abstract][Full Text] [Related]
37. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.
Asano T; McIntyre BW; Bednarczyk JL; Wygant JN; Kleinerman ES
Oncol Res; 1995; 7(5):253-7. PubMed ID: 8534931
[TBL] [Abstract][Full Text] [Related]
38. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
39. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
[TBL] [Abstract][Full Text] [Related]
40. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]